Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Inflazome Ltd.
A new UK company, Poolbeg Pharma, has been set up to develop new anti-infectives in an efficient manner, and already has a repositioned MAP kinase inhibitor for the treatment of severe influenza ready for Phase II studies.
The impact of the coronavirus pandemic on the size of the pharma R&D pipeline in 2020 could be felt in a number of ways.
Private Company Edition: China-focused Nuance Pharma led recent venture capital deals with a $181m series D round, RayzeBio closed a $105m series B and SciNeuro launched with $100m plus other notable rounds from Edgewise, Reneo, BioAge and others.
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.